TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
TuHURA Biosciences (NASDAQ: HURA) announced that research showing Delta Opioid Receptor (DOR) expression on tumor-associated myeloid cells was selected for an oral presentation at the 67th ASH Annual Meeting (Dec 6–9, 2025).
Key findings include the first demonstration of DOR expression on MDSCs and TAMs, evidence that DOR inhibition reprograms multiple MDSC- and TAM-mediated immunosuppressive mechanisms, and collaborative data from The Moffitt Cancer Center showing DOR+ MDSCs in MDS patients with restoration of stem cell proliferation after DOR inhibition.
TuHURA will present an oral talk on Dec 7, 2025, plus two poster presentations Dec 6–7, 2025, highlighting DOR antagonism as a potential strategy to overcome resistance to cancer immunotherapies.
TuHURA Biosciences (NASDAQ: HURA) ha annunciato che una ricerca che mostra l'espressione del recettore delta degli oppioidi (DOR) sulle cellule mieloidi associate al tumore è stata selezionata per una presentazione orale al 67° ASH Annual Meeting (6-9 dicembre 2025).
Tra i principali risultati: la prima dimostrazione di espressione di DOR su MDSC e TAM, evidenze che l'inibizione del DOR riprogramma molteplici meccanismi immunosoppressivi mediati da MDSC e TAM, e dati collaborativi dal Moffitt Cancer Center che mostrano DOR+ MDSC in pazienti con MDS con ripristino della proliferazione delle cellule staminali dopo l'inibizione del DOR.
TuHURA terrà una relazione orale il 7 dicembre 2025, oltre a due poster dal 6 al 7 dicembre 2025, evidenziando l'antagonismo del DOR come possibile strategia per superare la resistenza alle immunoterapie anticancro.
TuHURA Biosciences (NASDAQ: HURA) anunció que una investigación que muestra la expresión del Receptor Delta de Opioides (DOR) en células mieloides asociadas al tumor fue seleccionada para una presentación oral en la 67th ASH Annual Meeting (del 6 al 9 de diciembre de 2025).
Los hallazgos clave incluyen la primera demostración de expresión de DOR en MDSCs y TAMs, evidencia de que la inhibición de DOR reprograma múltiples mecanismos inmunosupresores mediados por MDSCs y TAMs, y datos colaborativos del The Moffitt Cancer Center que muestran DOR+ MDSCs en pacientes con MDS con restauración de la proliferación de células madre tras la inhibición de DOR.
TuHURA presentará una charla oral el 7 de diciembre de 2025, además de dos pósters del 6 al 7 de diciembre de 2025, destacando el antagonismo del DOR como una estrategia potencial para superar la resistencia a las inmunoterapias oncológicas.
TuHURA Biosciences (NASDAQ: HURA)는 종양 관련 골수구 제1세대(myeloid) 세포에서 델타 오피오이드 수용체(DOR) 발현이 제67회 ASH 연례회의에서 구두 발표로 선택되었다고 발표했습니다(2025년 12월 6-9일).
주요 발견으로는 첫 번째로 MDSC 및 TAM에서의 DOR 발현의 시연, DOR 억제가 다수의 MDSC 및 TAM 매개 면역억제 메커니즘을 재조정한다는 증거, 그리고 The Moffitt Cancer Center의 협력 데이터가 DOR+ MDSC가 MDS 환자에서 발견되며 DOR 억제로 줄기세포 증식이 회복됨을 보여준다는 점이 포함됩니다.
TuHURA는 2025년 12월 7일 구두 발표를 시작으로 12월 6-7일에 두 편의 포스터 발표를 발표할 예정이며, DOR 길항제가 암 면역치료에 대한 저항성을 극복할 수 있는 잠재적 전략으로 부각될 것이라고 강조합니다.
TuHURA Biosciences (NASDAQ: HURA) a annoncé que des recherches montrant l'expression du récepteur Delta des opioïdes (DOR) sur les cellules myéloïdes associées à la tumeur ont été sélectionnées pour une présentation orale lors du 67e ASH Annual Meeting (du 6 au 9 décembre 2025).
Les résultats clés incluent la première démonstration de l'expression du DOR sur les MDSC et les TAM, la preuve que l'inhibition du DOR reprogramme plusieurs mécanismes immunosuppressifs médiés par les MDSC et les TAM, et des données collaboratives du Moffitt Cancer Center montrant des MDSC DOR+ chez des patients atteints de MDS avec une restauration de la prolifération des cellules souches après l'inhibition du DOR.
TuHURA présentera une communication orale le 7 décembre 2025, ainsi que deux posters les 6 et 7 décembre 2025, mettant en lumière l'antagonisme du DOR comme stratégie potentielle pour surmonter la résistance aux immunothérapies anticancéreuses.
TuHURA Biosciences (NASDAQ: HURA) gab bekannt, dass eine Studie, die die Expression des Delta-Opioid-Rezeptors (DOR) auf tumorassoziierten Myeloidzellen zeigt, für eine mündliche Präsentation auf dem 67. ASH Annual Meeting (6.–9. Dezember 2025) ausgewählt wurde.
Zu den wichtigsten Ergebnissen gehören die erstmalige Demonstration der DOR-Expression bei MDSCs und TAMs, der Hinweis, dass die DOR-Hemmung mehrere von MDSC- und TAM-vermittelte Immununterdrückungsmechanismen neu programmiert wird, sowie kollaborative Daten vom Moffitt Cancer Center, die DOR+ MDSCs bei MDS-Patienten mit Wiederherstellung der Stammzellproliferation nach DOR-Hemmung zeigen.
TuHURA wird am 7. Dezember 2025 einen mündlichen Vortrag halten, zudem zwei Poster vom 6. bis 7. Dezember 2025 vorstellen, und die DOR-Antagonisierung als potenzielle Strategie zur Überwindung der Resistenz gegen Krebs-Immuntherapien hervorheben.
TuHURA Biosciences (NASDAQ: HURA) أعلنت أن البحث الذي يظهر تعبير مستقبل Delta للأفيونيات (DOR) على خلايا الميلود المرتبطة بالورم قد اختير لعرض شفهي في الاجتماع السنوي الـ67 لجمعية ASH (6-9 ديسمبر 2025).
وتشمل النتائج الرئيسية أول عرض لـ تعبير DOR على MDSCs و TAMs، وأدلة أن إيقاف DOR يعيد برمجة عدة آليات مناعية مثبطة Mediated by MDSC و TAM، وبيانات تعاونية من The Moffitt Cancer Center تُظهر وجود DOR+ في MDS لدى مرضى MDS مع استعادة تكاثر الخلايا الجذعية بعد تثبيط DOR.
سيقدم TuHURA محاضرة شفهية في 7 ديسمبر 2025، بالإضافة إلى عرضين ملتصقين في 6-7 ديسمبر 2025، مبرزاً أن تثبيط DOR قد يكون استراتيجية محتملة للتغلب على مقاومة العلاجات المناعية السرطانية.
- None.
- None.
Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy
The first demonstration that DOR is expressed on Tumor-Associated Macrophages (TAMs), with DOR inhibition modulating their immunosuppressive capabilities
Presentation from The Moffitt Cancer Center in collaboration with TuHURA scientists demonstrating the presence of the DOR on MDSCs from patients with myeloid dysplastic syndrome (MDS) and restoration of stem cell proliferation with DOR inhibition
"We are pleased to present evidence demonstrating the expression of the DOR on MDSCs and TAMs, both of which are important immune suppressing cellular components of the body's immune system that provide the ability to regulate inflammation and autoimmunity," stated Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "With our discovery of DOR expression, and that DOR activation is coupled to mechanisms by which both MDSCs and TAMs contribute to the immunosuppressive phenotype of the tumor microenvironment, we believe that the DOR represents a novel shared target for pharmacologic intervention to overcome resistance to cancer immunotherapies. TuHURA Biosciences is eager to leverage our discoveries around the DOR to develop highly potent and selective DOR inhibitors to create a new class of immune-modulating ADCs by linking a DOR inhibitor to our VISTA inhibiting antibody."
Oral Presentation Details:
Title: Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
Session: 201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis
Abstract Number: 14322
Presenter: Mike Turner, Ph.D. Vice President Immunology
Date and Time: December 7, 2025, from 5:15 – 5:30 PM ET
Location: W314 – OCC
Poster Presentation Details:
Title: Delta Opioid Receptor (DOR): A Novel Target for Reprogramming Tumor-Associated Macrophage (TAM) Immunosuppressive Phenotype to Overcome Acquired Resistance and Enhance the Effectiveness of Cancer Immunotherapies
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Abstract Number: 2568
Presenter: Krit Ritthipichai, D.V.M., Ph.D., Director of Immunology, TuHURA Biosciences
Date and Time: December 6, 2025, from 5:30 – 7:30 PM ET
Location: West Halls B3-B4 – OCCC
Additionally, The Moffitt Cancer Center, under its collaborative work with TuHURA, will present a poster outlining the pathogenic role of DOR expressing MDSCs in patients with myeloid dysplastic syndrome (MDS). Collectively, these three presentations at ASH highlight the potential of DOR antagonism as a potential effective strategy warranting clinical investigation.
Title: Delta opioid receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes
Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster II
Abstract Number: 15332
Presenter: Erika Eksioglu, M.D., Department of Immunology, Moffitt Cancer Center
Date and Time: December 7, 2025, from 6:00 – 8:00 PM ET
Location: West Halls B3-B4 – OCCC
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb asset moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding TuHURA's Delta Opioid Receptor Technology, its IFx-Hu2.0 product candidate and Phase 3 trial, and its TBS-2025 asset, and any developments or results in connection therewith and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-discovery-research-on-targeting-the-delta-opioid-receptor-dor-to-reprogram-myeloid-derived-suppressor-cells-mdscs-selected-for-oral-presentation-at-the-67th-ash-annual-meeting-and-exposition-302602298.html
SOURCE TuHURA Biosciences, Inc.
FAQ
What will TuHURA (HURA) present at ASH 2025 about the Delta Opioid Receptor?
When is TuHURA's oral presentation at the 67th ASH Annual Meeting (HURA)?
Which collaborators contributed to TuHURA's DOR findings presented at ASH (HURA)?
What is the potential clinical implication of TuHURA's DOR research (HURA)?
Where and when are TuHURA's poster presentations at ASH 2025 (HURA)?
